Purple Biotech
Purple Biotech Ltd. is a clinical-stage company dedicated to developing first-in-class therapies that address tumor immune evasion and drug resistance. Its pipeline includes innovative therapies such as CM24, NT219, and the CAPTN-3 platform, targeting mechanisms like CEACAM1, IRS1/2, and STAT3, and employing advanced biotechnological platforms and clinical programs. The company aims to improve treatment outcomes for cancer patients through its novel immunotherapies and targeted approaches.
Industries
Nr. of Employees
small (1-50)
Purple Biotech
4 Oppenheimer St. Science Park, Rehovot, Israel 7670104
Products
CM24
Humanized monoclonal antibody developed to block a tumor-associated immune-regulatory target implicated in tumor immune evasion; evaluated clinically in combination with PD-1 inhibition and chemotherapy in pancreatic cancer.
NT219
Small-molecule dual inhibitor that targets IRS1/2 and STAT3 pathways, developed to inhibit resistance mechanisms and modulate tumor signaling; advanced through Phase 1 and into Phase 2 combination studies.
CAPTN-3 platform
Preclinical platform of conditionally-activated tri-specific antibody scaffolds that combine a protease-cleavable mask with T-cell engager, NK-cell engager and tumor antigen-targeting arms to localize immune activation to tumors.
IM1240 (lead tri-specific candidate)
Lead tri-specific antibody candidate built on the CAPTN-3 scaffold targeting a tumor-associated antigen expressed in multiple solid tumors; demonstrated preclinical tumor regression in xenograft models.
CM24
Humanized monoclonal antibody developed to block a tumor-associated immune-regulatory target implicated in tumor immune evasion; evaluated clinically in combination with PD-1 inhibition and chemotherapy in pancreatic cancer.
NT219
Small-molecule dual inhibitor that targets IRS1/2 and STAT3 pathways, developed to inhibit resistance mechanisms and modulate tumor signaling; advanced through Phase 1 and into Phase 2 combination studies.
CAPTN-3 platform
Preclinical platform of conditionally-activated tri-specific antibody scaffolds that combine a protease-cleavable mask with T-cell engager, NK-cell engager and tumor antigen-targeting arms to localize immune activation to tumors.
IM1240 (lead tri-specific candidate)
Lead tri-specific antibody candidate built on the CAPTN-3 scaffold targeting a tumor-associated antigen expressed in multiple solid tumors; demonstrated preclinical tumor regression in xenograft models.
Services
Collaborative translational research agreements to evaluate immune-regulatory mechanisms and validate candidate activity across patient-derived tumor screens.
Operational and scientific collaboration to support investigator-led Phase 2 clinical studies conducted with academic partners, including protocol alignment and translational biomarker support.
Preparation and dissemination of scientific posters, abstracts, and peer-reviewed manuscripts to report preclinical and clinical findings.
Collaborative translational research agreements to evaluate immune-regulatory mechanisms and validate candidate activity across patient-derived tumor screens.
Operational and scientific collaboration to support investigator-led Phase 2 clinical studies conducted with academic partners, including protocol alignment and translational biomarker support.
Preparation and dissemination of scientific posters, abstracts, and peer-reviewed manuscripts to report preclinical and clinical findings.
Expertise Areas
- Early- and mid-stage oncology clinical development
- Biomarker-driven patient selection and translational biomarker strategies
- Multi-specific antibody engineering and conditional activation designs
- Small-molecule dual-target oncology drug development
Key Technologies
- Tri-specific and multi-specific antibody scaffolds
- Protease-cleavable masking/capping for conditional activation
- T-cell engager modalities
- NK-cell engager modalities
News & Updates
Purple Biotech announced the presentation of new preclinical data on its CAPTN-3 platform at the EACR 2025 Congress, highlighting the platform's ability to create tri-specific antibodies that activate both innate and adaptive immune systems to target tumors.
The company announced the start of a Phase 2 clinical trial evaluating NT219 in combination with pembrolizumab and cetuximab for head and neck squamous cell carcinoma, in collaboration with the University of Colorado.
Purple Biotech announced a poster presentation at EACR 2025 regarding its CAPTN-3 tri-specific antibody platform, emphasizing its potential in cancer immunotherapy.
The company reported positive clinical trial results for CM24 and NT219, and promising preclinical data for CAPTN-3, supporting its strategic development and potential for multiple cancer indications.
Purple Biotech announced the presentation of new preclinical data on its CAPTN-3 platform at the EACR 2025 Congress, highlighting the platform's ability to create tri-specific antibodies that activate both innate and adaptive immune systems to target tumors.
The company announced the start of a Phase 2 clinical trial evaluating NT219 in combination with pembrolizumab and cetuximab for head and neck squamous cell carcinoma, in collaboration with the University of Colorado.
Purple Biotech announced the presentation of new preclinical data on its CAPTN-3 platform at the EACR 2025 Congress, highlighting the platform's ability to create tri-specific antibodies that activate both innate and adaptive immune systems to target tumors.
The company announced the start of a Phase 2 clinical trial evaluating NT219 in combination with pembrolizumab and cetuximab for head and neck squamous cell carcinoma, in collaboration with the University of Colorado.
Purple Biotech announced a poster presentation at EACR 2025 regarding its CAPTN-3 tri-specific antibody platform, emphasizing its potential in cancer immunotherapy.
The company reported positive clinical trial results for CM24 and NT219, and promising preclinical data for CAPTN-3, supporting its strategic development and potential for multiple cancer indications.
Purple Biotech announced the presentation of new preclinical data on its CAPTN-3 platform at the EACR 2025 Congress, highlighting the platform's ability to create tri-specific antibodies that activate both innate and adaptive immune systems to target tumors.
The company announced the start of a Phase 2 clinical trial evaluating NT219 in combination with pembrolizumab and cetuximab for head and neck squamous cell carcinoma, in collaboration with the University of Colorado.